他克莫司联合糖皮质激素与环磷酰胺联合糖皮质激素治疗膜性肾病的两年随访研究
结果显示cCTX/GCs组在18和24个月时的缓解率及持续缓解率均显著高于TAC/GCs组,且TAC/GCs组复发率显著更高。
要点
- 24个月时cCTX/GCs组持续缓解率80%显著高于TAC/GCs组43%(P=0.002)。
- TAC/GCs组任何缓解后的复发率为40%,显著高于cCTX/GCs组的6.7%(P=0.007)。
- TAC/GCs治疗12个月后eGFR的显著下降在18和24个月时恢复正常。
核心结论
- 随机分组后2年,TAC/GCs组复发率高于cCTX/GCs组,长期来看cCTX/GCs优于TAC/GCs。
主要发现
- 18个月时TAC/GCs组和cCTX/GCs组缓解率分别为66%和89%(P=0.04)。
- 18和24个月时TAC/GCs组和cCTX/GCs组缓解率分别为60%和86%(P=0.03)。
- 18个月时TAC/GCs组和cCTX/GCs组无需额外免疫抑制的持续缓解率分别为57%和83%(P=0.03)。
- 24个月时TAC/GCs组和cCTX/GCs组持续缓解率分别为43%和80%(P=0.002)。
- 任何缓解后的复发率在TAC/GCs组和cCTX/GCs组分别为40%和6.7%(P=0.007)。
关键数值与推荐
- 复发性PMN中aPLA2R滴度与缓解或耐药相关(P=0.006)。
- TAC/GCs治疗12个月后eGFR的显著下降在18和24个月时恢复正常。
临床怎么用
- 对于PMN患者,选择cCTX/GCs方案可能获得更高的长期持续缓解率和更低的复发率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Both cCTX/GCs and CNIs are recommended as first-line agents in the management of PMN. The present study is an extended report of patients randomized to receive TAC/GCs or cCTX/GCs at 2 years post randomization. METHODS: Seventy patients enrolled in the clinical trial Tacrolimus Combined With Corticosteroids Versus Modified Ponticelli Regimen in Treatment of Idiopathic Membranous Nephropathy: Randomized Control Trial were followed quarterly between 12 and 24 months. At the end of 24 months, 3 patients were lost to follow-up. RESULTS: At 18 months, 66% and 89% (P = 0.04) were in remission in TAC/GCs and cCTX/GCs groups, respectively. At 18 and 24 months, 60% and 86% (P = 0.03) of cases were in remission in the TAC/GCs and cCTX/GCs groups, respectively. At 18 months, 57% and 83% (P = 0.03) of the patients in TAC/GCs and cCTX/GCs groups were in remission without need of any additional immunosuppression (persistent remission) and, at 24 months, 43% and 80% (P = 0.002) were in persistent remission in TAC/GCs and cCTX/GCs groups, respectively. Relapse rate after any remission was 40% and 6.7% in TAC/GCs and cCTX/GCs groups, respectively (P = 0.007). There was an association of aPLA2R titers with remission or resistance (P = 0.006) in relapsing PMN. The significant decrease in eGFR after 12 months of TAC/GCs therapy normalized at 18 and 24 months. DISCUSSION: At 2 years after randomization, relapse rates are higher for TAC/GCs compared with cCTX/GCs in PMN patients. Thus, cCTX/GCs are better than TAC/GCs in the longer term in PMN patients.
引用
- Ramachandran R, Yadav AK, Kumar V, et al. Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide. Kidney Int Rep. 2017. PMID: 29142979. doi:10.1016/j.ekir.2017.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。